Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:FBIO NASDAQ:IMMX NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.21-2.2%$5.84$4.31▼$9.56$169.58M1.03200,661 shs80,140 shsFBIOFortress Biotech$2.46+6.7%$2.64$1.66▼$4.53$81.22M1.16783,646 shs288,327 shsIMMXImmix Biopharma$9.63-4.7%$9.53$1.87▼$11.61$523.97M0.12821,421 shs184,824 shsVALNValneva$5.74-3.4%$7.19$5.06▼$12.25$494.25M1.7264,725 shs11,888 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+23.06%+27.00%+20.72%-17.85%+6.37%FBIOFortress Biotech+3.14%-4.17%-4.96%-36.29%+38.55%IMMXImmix Biopharma-3.72%+5.87%+2.54%+37.79%+410.10%VALNValneva+1.19%+6.83%-2.46%-41.07%-7.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.21-2.2%$5.84$4.31▼$9.56$169.58M1.03200,661 shs80,140 shsFBIOFortress Biotech$2.46+6.7%$2.64$1.66▼$4.53$81.22M1.16783,646 shs288,327 shsIMMXImmix Biopharma$9.63-4.7%$9.53$1.87▼$11.61$523.97M0.12821,421 shs184,824 shsVALNValneva$5.74-3.4%$7.19$5.06▼$12.25$494.25M1.7264,725 shs11,888 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+23.06%+27.00%+20.72%-17.85%+6.37%FBIOFortress Biotech+3.14%-4.17%-4.96%-36.29%+38.55%IMMXImmix Biopharma-3.72%+5.87%+2.54%+37.79%+410.10%VALNValneva+1.19%+6.83%-2.46%-41.07%-7.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.25Hold$13.00109.34% UpsideFBIOFortress Biotech 2.00Hold$17.00592.46% UpsideIMMXImmix Biopharma 2.50Moderate Buy$18.2589.61% UpsideVALNValneva 2.20Hold$11.98108.62% UpsideCurrent Analyst Ratings BreakdownLatest DERM, FBIO, VALN, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2026VALNValneva The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$4.904/21/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DERMJourney Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026VALNValneva GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.003/30/2026IMMXImmix Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$14.00 ➝ $15.003/27/2026FBIOFortress Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/27/2026IMMXImmix Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$23.003/27/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $15.003/26/2026DERMJourney Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.003/25/2026IMMXImmix Biopharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.003/16/2026FBIOFortress Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$61.86M2.74N/AN/A$0.96 per share6.47FBIOFortress Biotech$63.26M1.29N/AN/A$2.00 per share1.23IMMXImmix BiopharmaN/AN/AN/AN/A$1.55 per shareN/AVALNValneva$156.33M3.16N/AN/A$1.39 per share4.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$11.43M-$0.47N/A4.50N/A-14.82%-37.36%-11.02%N/AFBIOFortress Biotech$6.82M-$0.13N/A1.63N/A10.77%-41.20%-11.53%N/AIMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%6/3/2026 (Estimated)VALNValneva-$130.33M-$1.87N/A3.15N/A-88.87%-95.00%-31.90%N/ALatest DERM, FBIO, VALN, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/13/2026Q1 2026DERMJourney Medical-$0.07-$0.08-$0.01-$0.08$15.47 million$15.96 million5/13/2026Q1 2026VALNValneva-$0.21-$0.42-$0.21-$0.42$54.69 million$36.16 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A3/31/2026Q4 2025FBIOFortress Biotech$0.11-$0.21-$0.32-$0.21$26.17 million$16.08 million3/31/2026Q4 2025VALNValnevaN/A-$0.42N/A-$0.42N/A$35.77 million3/25/2026Q4 2025DERMJourney Medical-$0.06-$0.04+$0.02-$0.04$18.86 million$16.08 million3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A2/15/2026Q4 2025 TUVALNValnevaN/A-$0.68N/A-$0.68N/A$55.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical0.791.791.53FBIOFortress Biotech0.842.492.30IMMXImmix BiopharmaN/A8.7510.01VALNValneva1.522.381.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%FBIOFortress Biotech96.51%IMMXImmix Biopharma11.26%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%FBIOFortress Biotech28.50%IMMXImmix Biopharma30.30%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9027.33 million23.22 millionN/AFBIOFortress Biotech17033.22 million23.75 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableVALNValneva70086.11 million73.27 millionNot OptionableDERM, FBIO, VALN, and IMMX HeadlinesRecent News About These CompaniesValneva SE (VALN) Q1 2026 Earnings Call TranscriptMay 13 at 11:39 PM | seekingalpha.comValneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...May 13 at 11:39 PM | uk.finance.yahoo.comValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccinesMay 13 at 11:39 PM | fiercebiotech.comFValneva Q1 Earnings Call HighlightsMay 13 at 3:09 PM | marketbeat.comValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13 at 1:00 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNMay 7, 2026 | prnewswire.comValneva (NASDAQ:VALN) vs. PURE Bioscience (OTCMKTS:PURE) Critical SurveyMay 7, 2026 | americanbankingnews.comVALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026May 5, 2026 | globenewswire.comValneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026May 5, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 30, 2026 | prnewswire.comValneva Announces the Successful Completion of an €84 million Reserved OfferingApril 30, 2026 | globenewswire.comValneva (VALN) Expected to Announce Earnings on WednesdayApril 29, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNApril 28, 2026 | globenewswire.comAs tick season drags longer, Pfizer hopes to release a Lyme disease vaccine in 2027April 27, 2026 | politifact.comPValneva (NASDAQ:VALN) Downgraded by Wall Street Zen to Strong SellApril 25, 2026 | marketbeat.comValneva's Commercial Crossroads: A Vaccine Maker's Pivotal YearApril 23, 2026 | aktiencheck.deAValneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst DowngradeApril 22, 2026 | marketbeat.comValneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by AnalystsApril 22, 2026 | marketbeat.comValneva (NASDAQ:VALN) Cut to "Sell" at The Goldman Sachs GroupApril 22, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNApril 21, 2026 | globenewswire.comA vaccine for Lyme disease could be on the horizonApril 20, 2026 | sciencenews.orgSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDERM, FBIO, VALN, and IMMX Company DescriptionsJourney Medical NASDAQ:DERM$6.21 -0.14 (-2.20%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Fortress Biotech NASDAQ:FBIO$2.46 +0.16 (+6.74%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Immix Biopharma NASDAQ:IMMX$9.62 -0.48 (-4.70%) As of 10:57 AM Eastern This is a fair market value price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Valneva NASDAQ:VALN$5.74 -0.20 (-3.37%) As of 10:49 AM Eastern This is a fair market value price provided by Massive. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Dividend Growth or High Yield: The Income Investor's Bet Karman: Defense Darling's Outlook Strengthens After 40% Drop Nebius Upside Expands as AI Feedback Loop Intensifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
